Holdaway I M, Friesen H G
Cancer Res. 1976 May;36(5):1562-7.
Dimethylbenzanthracene-induced rat mammary tumors were defined as either prolactin responsive or prolactin independent on the basis of growth response to prolactin administration. There was no difference in tumor binding of prolactin between the two groups when tumors were biopsied before treatment. Prolactin binding was, however, significantly higher in responding tumors when biopsies were obtained following treatment. By contrast, when tumors were defined as responsive or independent on the basis of response to suppression of serum prolactin with bromoergocryptine, there was significantly higher prolactin binding in the responsive than in the independent group both before and after treatment. During serial treatment with prolactin followed by bromoergocryptine, there was a progressive decline in prolactin binding to tumor biopsies, particularly in prolactin-independent tumors. Prolactin binding to pretreatment tumor biopsies thus did not predict which tumors would respond to administration of prolactin but, for the total group, did indicate tumors likely to regress with prolactin withdrawal. However, the correlation between prolactin binding and tumor regression following hormone withdrawal was not sufficiently strong to permit reliable prediction of behavior for individual tumors. Prolactin-independent growth was associated with decreased prolactin binding to tumor tissue, particularly following manipulation of serum prolactin levels.
根据对催乳素给药的生长反应,将二甲基苯并蒽诱导的大鼠乳腺肿瘤定义为催乳素反应性或催乳素非依赖性。在治疗前对肿瘤进行活检时,两组肿瘤的催乳素结合情况没有差异。然而,在治疗后进行活检时,反应性肿瘤中的催乳素结合显著更高。相比之下,当根据对溴隐亭抑制血清催乳素的反应将肿瘤定义为反应性或非依赖性时,在治疗前后,反应性组中的催乳素结合均显著高于非依赖性组。在用催乳素随后用溴隐亭进行连续治疗期间,肿瘤活检中催乳素结合呈逐渐下降趋势,尤其是在催乳素非依赖性肿瘤中。因此,催乳素与治疗前肿瘤活检的结合不能预测哪些肿瘤会对催乳素给药产生反应,但对于整个组来说,确实表明肿瘤可能会随着催乳素撤药而消退。然而,催乳素结合与激素撤药后肿瘤消退之间的相关性不够强,无法可靠地预测单个肿瘤的行为。催乳素非依赖性生长与肿瘤组织中催乳素结合减少有关,尤其是在血清催乳素水平受到调控之后。